FDA approves Lupin’s generic Dovonex Scalp Solution
The Food and Drug Administration has approved Lupin’s generic of Leo Pharmaceutical Products’ Dovonex Scalp Solution (calcipotriene topical solution, 0.005%). The product is indicated for the topical treatment of moderately severe psoriasis on the scalp.
According to IQVIA data, the product had U.S. sales of roughly $5.9 million for the 12 months ended October 2017.
ANI buys 4 products from AstraZeneca
ANI Pharmaceuticals has acquired four potential new drugs from AstraZeneca, the Baudette., Minn.-based company announced recently. The company acquired the new drug applications and U.S. marketing rights to Atacand, Atacand HCT, Arimidex and Casodex for $46.5 million in cash, royalties and sales-based milestones.
“This acquisition complements our brand and generic strategies and further expands and diversifies our commercial portfolio,” ANI president and CEO Arthur Przybyl said. “Importantly, ANI has the capability to manufacture and package all of the products at our containment facility in Baudette, Minn. The addition of these assets will be material to our revenue and EBITDA in 2018, and we plan to provide financial guidance for 2018 at the time of our next regularly scheduled earnings announcement.”
Atacand is indicated to treat hypertension and heart failure; Atacand HCT is indicated to treat hypertension; Arimidex is indicated to treat certain types of breast cancer in postmenopausal women; and Casodex is indicated as a combination therapy in certain types of carcinoma of the prostate, while its 150-mg dosage strength is not yet approved for use. The four drugs collectively generated $19 million for the 12 months ended October 2017, according to IQVIA data.
Stony Creek Brewery launches Crankenstein IPA series in cans
Stony Creek Brewery has announced the launch of their Crankeinstein India Pale Ale, or IPA. This new series will feature different numbered versions called, “Hatchlings” which merge the styles influences of the West Coast and New England. The first product in the line is set to be released January 15.
The Branford, Conn.-based company describes the flavors found in each can of Crankenstein as clean, dry, bright with a balance of bitterness. The product’s feel is entirely New England which is marked by a cloudy appearance, low bitterness, juicy hop flavors and aromas, the brand added.
"We took the New England style and added a little west coast attitude to it," lead brewer Gordon Whelpley, said. "We increased the bitterness ever so slightly, dried out the finish a touch and filtered the beer bright. This still leaves the same smooth body and huge juicy hop flavor and aromas, just balanced a bit better by the dryness and clean bright finish. It really is the best of both worlds."
The series will launch with Hatchling 001, a 7.2% ABV IPA brewed with Simpsons Golden Promise Malt, Pilsner Malt and copious amounts of Simcoe and Citra hops that contain notes of passionfruit and tropical citrus.
The 16-oz. cans of Crankenstein IPA will be sold in limited amounts as a pack of four in locations where Stony Creek Beer is currently available. A new Hatchling will be released to consumers every two months.